Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04054024
Other study ID # H-19011013
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 28, 2019
Est. completion date October 1, 2021

Study information

Verified date November 2019
Source Danish Headache Center
Contact Stine Maarbjerg, MD, PhD
Phone 004538633525
Email stine.maarbjerg@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A placebo-controlled, double-blind, randomized proof-of-concept study to evaluate the efficacy and tolerability of the CGRP receptor antibody erenumab in treating pain experienced by subjects with TN.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date October 1, 2021
Est. primary completion date October 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- A diagnosis of primary TN (idiopathic or classical) according to criteria of The Interna-tional Classification of Headache Disorders 3rd edition (1).

- Age between 18 and 85 years.

- Subjects must have a minimum mean of three TN related pain paroxysms per day with a mean ADP of 4 to 10, inclusive, on the 11-point NRS (0= no pain; 10= maximum pain imaginable) during the 7-day screening phase to enter the baseline phase.

- Subjects must have a minimum mean of three TN related pain paroxysms per day with a mean ADP of 4 to 10, inclusive, on the 11-point NRS (0= no pain; 10= maximum pain imaginable) during the 4-week baseline phase to enter the treatment phase (to be randomized).

- Fertile women must use safe contraceptives and present with a negative u-HCG at visit 1. Safe contraceptives are defined as intra-uterine devices, contraceptive pills or implants and surgical sterilization.

Exclusion Criteria:

- Significant cardiovascular and cerebrovascular disease such as ischemic heart disease, previous myocardial infarction or previous stroke or transient ischemic attack, major CVD interventions.

- Language difficulties.

- Poor compliance, i.e. unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures to the best of the sub-ject's and investigator's knowledge.

- Severe psychiatric disease.

- Anamnestic or clinical symptoms of any kind that are deemed relevant for study partici-pation by the physician who examines the patient.

- Taking any TN-medication, where the prescribed daily dose has changed within 2 weeks prior to the baseline period (refer to section 6.4 for the list of these medications).

- Pregnant or breastfeeding, or is a female expecting to conceive during the study, includ-ing through 4 weeks after treatment.

- Female subject of childbearing potential who is unwilling to use an acceptable method of effective contraception during the study. Acceptable methods of effective birth control include not having intercourse (true abstinence, when this is in line with the preferred and usual lifestyle of the subject), hormonal birth control methods (pills, shots/injections, implants, or patches), intrauterine devices, surgical contraceptive methods (vasectomy with medical assessment of the surgical success of this procedure or bilateral tubal ligation), or two barrier methods (each partner must use one barrier method) with spermicide - males must use a condom with spermicide; females must choose either a diaphragm with spermicide, OR cervical cap with spermicide, OR contraceptive sponge with spermicide. Female subjects not of childbearing potential are defined as any female who: is post-menopausal by history, defined as:

Age = 55 years with cessation of menses for 12 or more months, OR Age < 55 years but no spontaneous menses for at least 2 years, OR Age < 55 years and spontaneous menses within the past 1 year, but currently amenorrheic (eg, spontaneous or secondary to hysterectomy), AND with postmenopausal gonadotro-pin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L) or postmenopausal estradiol levels (< 5 ng/dL) or according to the definition of "postmeno-pausal range" for the laboratory involved. OR o Underwent bilateral oophorectomy OR o Underwent hysterectomy OR o Underwent bilateral salpingectomy.

- Known sensitivity to any component of erenumab.

- Member of investigational site staff or relative of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Erenumab
140 mg Erenumab
Placebos
Saline

Locations

Country Name City State
Denmark Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup Glostrup

Sponsors (1)

Lead Sponsor Collaborator
Danish Headache Center

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects classified as responders at the end of the evaluation period. A subject who meets the following criterion will be classified as a responder:
Has a reduction of = 30% in mean average daily pain intensity score (mean ADP) assessed using the 11-point numerical rating scale (NRS) during the evaluation period (week 1-4) compared with baseline (weeks -4 to -1). Patients that are protocol violators, e.g., patients having to increase current medications or undergoes surgery in the evaluation period as well as pa-tients who drop out due to worsening of symptoms or side effects will be recorded as non-responders.
4 weeks after randomization
Secondary Secondary outcome measures proportion of subjects reaching =50% reduction in mean ADP (average daily pain) during the evaluation period (week 1-4) compared with baseline (week -4 to -1).
proportion of subjects reaching =75% reduction in mean ADP during the evaluation period (week 1-4) compared with baseline (week -4 to -1).
subjects with a response in number of paroxysms at evaluation period.
proportion of subjects with a Patient Global Impression of Change (PGIC) scale response at evaluation period.
Due to word limitations not all secondary outcome measures were explaned in detail and/or registered.
4 weeks after randomization
See also
  Status Clinical Trial Phase
Recruiting NCT05152368 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy Phase 1
Recruiting NCT02801630 - An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia N/A
Completed NCT02473016 - Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia Phase 2
Recruiting NCT01364259 - A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia Phase 3
Completed NCT01364272 - Diffusion Tensor Imaging Magnetic Resonance Imaging (DTI MRI) as a Correlate to Pain Relief and Facial Numbness in Patients Following Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia
Completed NCT00913107 - Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia Phase 2/Phase 3
Completed NCT00603694 - Hippocampal Radiation Exposure and Memory N/A
Recruiting NCT04996199 - Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial Phase 4
Completed NCT06240494 - Predictive Factors in Maxillary and Mandibular Nerve Radiofrequency Treatment for Trigeminal Neuralgia
Completed NCT05712993 - Comparative Study Between Transcoronoid and Infrazygomatic Anterior Maneuvers N/A
Completed NCT04371575 - Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients
Completed NCT03669744 - Regional Anesthesia in Refractory Trigeminal Neuralgia: 21 Cases Reported to the Limoges University Hospital
Completed NCT05032573 - Feasibility of Olive Oil for Reducing Facial Pain of Trigeminal Neuralgia N/A
Recruiting NCT05615714 - Paresthesia-free Peripheral Nerve Field Stimulation for Trigeminal Neuralgia (FreeST Trial) Phase 1/Phase 2
Not yet recruiting NCT05451251 - Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion N/A
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Withdrawn NCT01932255 - CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap N/A
Completed NCT05075707 - Comparison Between Magnetic Field and Laser Therapy in Management of Trigeminal Neuralgia N/A
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Recruiting NCT03331913 - Botulinum Toxin for Trigeminal Neuralgia Phase 3